NCT03357731

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

Conditions

• Heart Failure
• Cardiac Failure
• Reduced Ventricular Ejection Fraction

Interventions

Type	Name	Description
DRUG	HNO Donor	Infusion
DRUG	Nitroglycerin (NTG)	Infusion
OTHER	Placebo	Infusion

Timeline

• Start date: 2017-11-30
• Primary completion: 2019-05-10
• Completion: 2019-05-10
• First posted: 2017-11-30
• Last updated: 2020-07-27
• Results posted: 2020-07-27

Locations

18 sites across 4 countries: United States, Japan, Netherlands, United Kingdom

Regulatory

• FDA-regulated drug study